Direct evidence that IFN-1β functions as a tumor-suppressor protein

Journal of Interferon and Cytokine Research

Volumn 22, Issue 11, 2002, Pages 1089-1098

  Kaynor, Campbell ^a   Xin, Mei ^a   Wakefield, John ^b   Barsoum, James ^a   Qin, Xiao Qiang ^a,c  

^a BIOGEN   (United States)

^b Tranzyme Inc   (United States)

^c BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; BROXURIDINE; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER; CANCER INHIBITION; CARCINOGENICITY; CELL AGING; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; LENTIVIRINAE; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; APOPTOSIS; CELL AGING; CELL CYCLE; CELL LINE; CELL SURVIVAL; HIV; HUMANS; INTERFERON TYPE I, RECOMBINANT; KINETICS; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS;

LENTIVIRUS;

EID: 0036924160     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/10799900260442511     Document Type: Article

References (37)

1. Issacs, A., and Lindemann, J. (1957). Virus interference I: The interferon. Proc. R. Soc. Lond. 147, 258-267.
2. Lengyel, P. (1982). Biochemistry of interferons and their actions. Annu. Rev. Biochem. 51, 251-282.
3. Belardelli, F., and Gresser, I. (1996). The neglected role of type I interferon in the T cell response: Implications for its clinical use. Immunol. Today 17, 369-372.
4. Sen, G.C. (2001). Viruses and interferons. Annu. Rev. Microbiol. 55, 255-281.
5. Einhorn, S., and Grander, D. (1996). Why do so many cancer patients fail to respond to interferon therapy? J. Interferon Cytokine Res. 16, 275-281.
6. Qin, X.-Q., Tao, N., Dergay, A., Moy, P., Fawell, S., Davis, A., Wilson, J.M., and Barsoum, J. (1998). Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc. Natl. Acad. Sci. USA 95, 14411-14416.
7. Qin, X.-Q., Beckham, C., Brown, J.L., Lukashev, M., and Barsoum, J. (2001). Human and mouse IFN-β gene therapy exhibits different anti-tumor mechanisms in mouse models. Mol. Ther. 4, 356-363.
8. Brown, J.L., Barsoum, J., and Qin, X.-Q. (2002). CD4+ T helper cell-independent antitumor response mediated by murine IFN-β gene delivery in immunocompetent mice. J. Interferon Cytokine Res. 22, 719-728.
9. 1 arrest in the inhibition of tumor cell growth by interferon. Proc. Natl. Acad. Sci. USA 77, 1471-1475.
10. Fuse, A., and Kuwata, T. (1997). Inhibition of DNA synthesis of synchronized Rsa cells by human leukocyte interferon. J. Natl. Cancer Inst. 58, 891-896.
11. Kimchi, A. (1992). Cytokine triggered molecular pathways that control cell cycle arrest. J. Cell. Biochem. 50, 1-9.
12. Lundblad, D., and Lundgren, E. (1981). Block of glioma cell line in S by interferon. Int. J. Cancer 27, 749-754.
13. Oberg, K. (1992). The action of interferon alpha on human carcinoid tumors. Semin. Cancer Biol. 3, 35-41.
14. Qin, X.-Q., Runkel, L., Deck, C., Dedios, C., and Barsoum, J. (1997). Interferon-β induces S phase accumulation selectively in human transformed cells. J. Interferon Cytokine Res. 17, 355-367.
15. Kayagaki, N., Yamaguchi, N., Nakayama, M., Eto, H., Okumura, K., and Yagita, H. (1999). Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189, 1451-1460.
16. Tada, H., Maron, D.J., Choi, E.A., Barsoum, J., Lei, H., Xie, Q., Liu, W., Ellis, L., Moscioni, D., Tazelaar, J., Fawell, S., Qin, X., Propert, K.J., Davis, A., Fraker, D.L., Wilson, J.M., and Spitz, F.R. (2001). Systemic IFN-β gene therapy results in long-term survival in mice with established colorectal liver metastases. J. Clin. Invest. 108, 83-95.
17. Brickelmaier, M., Carmillo, A., Goelz, S., Barsoum, J., and Qin, X.-Q. (2002). Cytotoxicity of combinations of IFN-β and chemotherapeutic drugs. J. Interferon Cytokine Res. 22, 873-880.
18. Wu, X., Wakefield, J.K., Liu, H., Xiao, H., Kralovics, R., PRCHAL, J.T., and KAPPES, J.C. (2000). Development of a novel trans-lentiviral vector that affords predictable safety. Mol. Ther. 2, 47-55.
19. Dimri, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E.E., Linskens, M., Rubelj, I., Pereira-Smith, O., Peacocke, M., and Campisi, J. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 92, 9363-9367.
20. Xu, H.J., Zhou, Y., Ji, W., Perng, G.S., Kruzelock, R., Kong, C.T., Bast, R.C., Mills, G.B., Li, J., and Hu, S.X. (1997). Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene 15, 2589-2596.
21. 1 arrest associated with induction of p21WAF1/CIP1/SDI1, changes in the expression of p21-regulated genes, and a senescence-like phenotype. Cancer Res. 61, 7754-7762.
22. Duncan, E.L., Wadhwa, R., and Kaul, S.C. (2000). Senescence and immortalization of human cells. Biogerontology 1, 103-121.
23. Diaz, M.O., Ziemin, S., Le Beau, M.M., Pitha, P., Smith, S.P., Chilcote, R.R., and Rowley, J.D. (1988). Homozygou s deletion of the α- and/β-interferon genes in human leukemia and derived cell lines. Proc. Natl. Acad. Sci. USA 85, 5259-5293.
24. INK4, methylthioadenosine phosphorylase, and the α- and/β-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. Cancer Res. 56, 1083-1090.
25. Cheng, J.Q., Jhanwar, S.C., Lu, Y.Y., and Testa, J.R. (1993). Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. Cancer Res. 53, 4761-4763.
26. Lengyel, P. (1993). Tumor-suppressor genes: News about the interferon connection. Proc. Natl. Acad. Sci. USA 90, 5893-5895.
27. Koromilas, A.E., Roy, S., Barber, G.N., Katze, M.G., and Sonenberg, N. (1992). Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. Science 257, 1685-1689.
28. Meurs, E.F., Galabru, J., Barber, G.N., Katze, M.G., and Hovanessian, A.G. (1993). Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. USA 90, 232-236.
29. Fujita, T., Reis, L.F.L., Watanabe, N., Kimura, Y., Taniguchi, T., and Vilcek, J. (1989). Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways. Proc. Natl. Acad. Sci. USA 86, 9936-9940.
30. Zhou, A., Hassel, B.A., and Silverman, R. (1993). Expression cloning of 2-5A-dependent RNase: A uniquely regulated mediator of interferon action. Cell 72, 753-765.
31. Belardelli, F., and Gresser, I. (1996). The neglected role of type I interferon in the T-cell response: Implications for its clinical use. Immunol. Today 17, 369-372.
32. Hiscott, J., and Pitha, P.M. (2002). Interferon regulatory factors: Bridging antiviral defense, growth control, and immunoregulation. J. Interferon Cytokine Res. 22, 3-4.
33. Gresser, I., Maury, C., Kaido, T., Bandu, M.T., Tovey, M.G., Maunoury, M.T., Fantuzzi, L., Gessani, S., Greco, G., and Belardelli, F. (1995). The essential role of endogenous IFN alpha/beta in the anti-metastatic action of sensitized T lymphocytes in mice injected with Friend erythroleukemia cells. Int. J. Cancer 63, 726-731.
34. + T cells and IFN-alpha/beta. Int. J. Cancer 57, 538-543.
35. Kaido, T.J., Maury, C., and Gresser, I. (1995). Host CD4+ T lymphocytes are required for the synergistic action of interferonalpha/beta and adoptively transferred immune cells in the inhibition of visceral Esb metastases. Cancer Res. 55, 6133-6139.
36. Rogge, L., Barberis-Maino, L., Biffi, M., Passini, N., Presky, D.H., Gubler, U., and Sinigaglia, F. (1997). Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J. Exp. Med. 185, 825-831.
37. Tough, D.F., Borrow, P., and Sprent, J. (1996). Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272, 1947-1950.